O-118 The prevalence of metabolic syndrome and iron-deficiency anaemia in patients with localized prostate cancer

Methods: This was a prospective study of 58 histologically confirmed PCa patients diagnosed at the University Hospital of the West Indies between January 2023 and August 2025. Each participant provided blood for serum total prostate specific antigen (tPSA) and other biochemical tests iron profile [serum total iron binding capacity (TIBC), ferritin and folate levels]. Metabolic syndrome was determined using the criteria set forth by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) (2005). All data were analysed using the Statistical Package for Social Science version 22.0 and p<0.05 was deemed statistically significant.

Results: The urbanized regions of Jamaica (Kingston and St. Andrew) accounted for majority (64.5%) of PCa participants. The majority (93.2%) of participants had tPSA above 4.0 ng/mL equating to a mean of 38.9 ng/mL. Approximately 6.9% of participants demonstrated having three or more risk factors relating to the prevalence of metabolic syndrome. In examining the iron profile of all the PCa participants, over one-fifth (21.1%) showed decreased serum TIBC, 25.0% had increased serum ferritin levels and 16.7% presented withelevated serum folate levels.

Conclusion: The study showed a 6.9% prevalence in PCa patients with localized disease. The findings of elevated ferritin and folate, as well as decreased TIBC suggests that the dysregulation of iron metabolism, altered folate status and metabolic syndrome may be related to the progression of PCa. The iron profile could serve as complementary tests in monitoring treatment and prognosis of PCa.